Plavix, Clopidogrel News

Background -Non-ST-segment elevation myocardial infarction patients on home warfarin pose treatment concerns, due to potential increased risk of bleeding.

Just three months before the world's second-best-selling drug gets U.S. generic competition, a generic company has paid nearly $445 million to finally end a decadelong, twist-filled patent infringement battle with two heavyweight drugmakers over blood thinner Plavix.

The settlement following a lengthy legal battle against Apotex since 2002 was announced on Wednesday as Sanofi posted 2011 results with a warning that patent expiry would this year help depress earnings by 12-15 per cent.

Combining clopidogrel with aspirin did not prevent recurrent stroke deep in the brain, and even increased the risk of bleeding and death.

Clopidogrel is an inactive prodrug; it is converted to its active metabolite through the cytochrome P450 pathway, which also metabolizes calcium channel blockers .

On 1/6/12 Transgenomic Inc. filed an 8-K announcing a $3 million commitment by Third Security to purchase convertible promissory notes.

The anti-blood clot regimen that adds the drug clopidogrel to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

The anti-blood clot regimen that adds the drug clopidogrel to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

The anti-blood clot regimen that adds the drug clopidogrel to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

A Lehigh veteran has found himself in the middle of a controversy over a popular drug used to prevent stroke and heart attacks.

From the Deutsches Herzzentrum MA1 4nchen and 1. Medizinische Klinik, Klinikum rechts der Isar, Technische UniversitA t MA1 4nchen , Munich, Germany.

Bristol-Myers Squibb Co. reported a 76 percent increase in the fourth-quarter profit Thursday, driven in part by sales of a recently-approved diabetes drug and hefty charges a year earlier, though the drugmaker still fell short of Wall Street 's expectations.

Bristol-Myers Squibb Co. failed to beat analysts' fourth-quarter profit estimates as the company invested in new products and sales fell for Plavix and Avapro, top-selling pills that will face generic competition this year.

Hattiesburg Heart and Vascular, a division of Wesley Medical Group, is bringing advanced screening to the area in order to match patients with drugs that work better with their bodies.

"The most important thing is the ability to choose the best course of therapy, solely based on what is in the best interest of the patient." Coincident with the introduction of generics into the Canadian market, STI worked with the two manufacturers to deliver and rollout the national program, providing continuity of care for those patients who are ... (more)

It is interesting to note that the bleeding risk was the same for both doses. This was irrespective of whether patients were taking aspirin alone or a combination of aspirin and clopidogrel, whether they had renal failure, and even their age, although the higher dose had an increased trend toward major bleeding compared with the lower dose .

Antiplatelet therapy with aspirin is a cornerstone of secondary prevention in coronary artery disease , mainly to prevent recurrent ischemic events.

From the University of Alberta, Edmonton, Canada ; INSERM U-698, Assistance Publique-HA pitaux de Paris, and Universite Paris-Diderot, Paris, France ; Uppsala University Hospital, Uppsala, Sweden ; University of Sheffield, Sheffield, United Kingdom ; AstraZeneca, Wilmington, MA ; University of Heidelberg, Heidelberg, Germany ; Copenhagen University ... (more)

Patients who discontinued use of an antiplatelet agent such as clopidogrel prior to undergoing cardiac surgery to lower their bleeding risk and received intravenously the platelet inhibitor cangrelor achieved a higher rate of maintenance of platelet inhibition, compared to patients who received placebo, according to a study in the January 18 issue ... (more)

Background: Coronary artery bypass surgery is typically delayed until 5 days after last clopidogrel dose, waiting for restoration of platelet reactivity units .